Philippines - English - FDA (Food And Drug Administration)

pedia ogcare, inc. - zinc (as sulfate monohydrate) - syrup - 20 mg per 5 ml 55 mg per 5 ml

Philippines - English - FDA (Food And Drug Administration)

pedia ogcare, inc. - zinc (as sulfate monohydrate) - syrup (oral drops) - 10 mg/ml

Israel - English - Ministry of Health

medici medical ltd, israel - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; poliovirus type 1; poliovirus type 2; poliovirus type 3; prp of haemophilus infl. type b; tetanus toxoid - suspension for injection - pertactin (prn) 3 mcg ml; diphtheria toxoid 15 lf ml; tetanus toxoid 5 lf ml; pertussis toxoid vaccine 20 mcg ml; filamentous haemagglutinin (fha) 20 mcg ml; fimbrae tupes 2 + 3 (fim) 5 mcg ml; poliovirus type 1 40 du ml; poliovirus type 2 8 du ml; poliovirus type 3 32 du ml; prp of haemophilus infl. type b 10 mcg ml - bacterial and viral vaccines, combined - pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. in infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. children who have had natural pertussis can continue to receive pertussis - containing vaccines. human immunodeficiency virus (hiv) infected persons hiv- infected individuals, both asymptomatic and symptomatic, should be immunized with pediacel vaccine according to standard schedules.

Philippines - English - FDA (Food And Drug Administration)

pedia ogcare inc - chloramphenicol (as palmitate) - suspension - 125mg / 5ml

Philippines - English - FDA (Food And Drug Administration)

pedia ogcare inc. - cotrimoxazole - suspension - 400mg/ 80mg per 5ml

Philippines - English - FDA (Food And Drug Administration)

pedia ogcare inc - guaifenesin , salbutamol - syrup - 50mg + 1mg/5ml

Philippines - English - FDA (Food And Drug Administration)

pedia ogcare, inc. - phenylephrine hydrochloride , brompheniramine maleate - syrup - 5 mg per 2 mg per 5 ml

Philippines - English - FDA (Food And Drug Administration)

pedia ogcare, inc. - phenylephrine hydrochloride , brompheniramine maleate - syrup (oral drops) - 1 mg/0.8 mg per ml

United States - English - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - ascorbic acid 80 mg in 4 ml - infuvite pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite pediatric is contraindicated in patients who have: infuvite pediatric has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. animal reproduction studies have not been conducted with infuvite pediatric (multiple vitamins injection). infuvite pediatric has not been studied in nursing mothers. lactating women may have vitamin requirements that exceed those of non-lactating women. caution should be exercised when infuvite pediatric is administered to nursing mothers. infuvite pediatric is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years

United States - English - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - ascorbic acid 80 mg in 5 ml - infuvite pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite pediatric is contraindicated in patients who have: infuvite pediatric has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. animal reproduction studies have not been conducted with infuvite pediatric (multiple vitamins injection). infuvite pediatric has not been studied in nursing mothers. lactating women may have vitamin requirements that exceed those of non-lactating women. caution should be exercised when infuvite pediatric is administered to nursing mothers. infuvite pediatric is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years